Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials
Related News

A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)

First Posted Date
2008-10-24
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
455
Registration Number
NCT00779545

Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)

Phase 4
Completed
Conditions
Infertility
Interventions
Drug: Marvelon
First Posted Date
2008-10-24
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
442
Registration Number
NCT00778999

Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)

Phase 4
Completed
Conditions
Allergies
Interventions
Drug: Desloratadine
Drug: Zyrtec® (cetirizine)
First Posted Date
2008-10-24
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
217
Registration Number
NCT00779116

Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)

Phase 4
Completed
Conditions
Allergic Airway Disease
Interventions
Drug: Placebo
Drug: Desloratadine
First Posted Date
2008-10-24
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
506
Registration Number
NCT00779636

MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)

Phase 3
Completed
Conditions
Rhinitis, Allergic
Interventions
Drug: montelukast sodium
First Posted Date
2008-10-13
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
120
Registration Number
NCT00771160

Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

Phase 3
Completed
Conditions
Bipolar 1 Disorder
Interventions
Drug: Asenapine
Drug: Placebo
First Posted Date
2008-10-02
Last Posted Date
2024-06-18
Lead Sponsor
Organon and Co
Target Recruit Count
367
Registration Number
NCT00764478

Elocon vs Fluticasone in Localized Psoriasis (P03197)

Phase 4
Completed
Conditions
Psoriasis
Interventions
Drug: Mometasone
Drug: Fluticasone
First Posted Date
2008-10-01
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
245
Registration Number
NCT00763529

Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)

First Posted Date
2008-09-29
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
2980
Registration Number
NCT00761527

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Phase 4
Completed
Conditions
Pain
Interventions
Drug: etoricoxib
First Posted Date
2008-09-23
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
500
Registration Number
NCT00757627

Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)

First Posted Date
2008-09-23
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
97
Registration Number
NCT00757562
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy